Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WAYNE HARPER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1376538926
CMS profile
197757
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$20.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Gift $20.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $20.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WAYNE HARPER

NPI 1376538926 · CMS profile ID 197757

Allopathic & Osteopathic Physicians / Internal Medicine

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376538926?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WAYNE HARPER, NPI 1376538926, CMS profile ID 197757. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376538926?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). WAYNE HARPER, NPI 1376538926, CMS profile ID 197757. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376538926?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
WAYNE HARPER, NPI 1376538926, CMS profile ID 197757, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1376538926?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $20.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $20.0006/03/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833593813 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $20.00 1
PY2023 $14.65 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $74,594.70 18
PY2021 Principal investigator $2,376,430.02 49
PY2020 Principal investigator $3,589,740.22 82
PY2019 Recipient $9,290.45 2
PY2019 Principal investigator $696,096.81 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

92 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 12/19/2019 Non-covered Recipient Entity
Wake Research Associates
HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV 2 No dispute reported 06/30/2026 691624977
Principal investigator 1 PFIZER INC. $5,377.08 12/04/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685371
Principal investigator 1 PFIZER INC. $866.78 11/28/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671668795
Principal investigator 1 PFIZER INC. $1,148.56 11/28/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671677079
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,890.00 11/19/2019 Non-covered Recipient Entity
M3 Wake Research, Inc
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023045
Principal investigator 1 PFIZER INC. $204.68 11/13/2019 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671663753
Principal investigator 1 PFIZER INC. $1,216.10 11/07/2019 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671663709
Principal investigator 1 PFIZER INC. $550.65 11/07/2019 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671663799
Principal investigator 1 PFIZER INC. $251.07 11/01/2019 Non-covered Recipient Entity
Wake Research Associates LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671673447
Principal investigator 1 PFIZER INC. $1,962.38 11/01/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685373
Principal investigator 1 PFIZER INC. $841.02 11/01/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671686247
Principal investigator 1 PFIZER INC. $33,040.61 10/22/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671685375
Principal investigator 1 PFIZER INC. $2,084.68 10/22/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671686185
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $812.79 10/16/2019 Non-covered Recipient Entity
M3 Wake Research, Inc
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023009
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,040.00 10/16/2019 Non-covered Recipient Entity
M3 Wake Research, Inc
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023019
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.62 10/16/2019 Non-covered Recipient Entity
M3 Wake Research, Inc
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023031
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,890.00 10/16/2019 Non-covered Recipient Entity
M3 Wake Research, Inc
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023041
Principal investigator 1 PFIZER INC. $1,402.25 10/10/2019 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671663707
Principal investigator 1 PFIZER INC. $552.50 10/10/2019 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671663755
Principal investigator 1 PFIZER INC. $4,647.25 10/08/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671686249
Principal investigator 1 PFIZER INC. $1,550.77 10/03/2019 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671663751
Principal investigator 1 Novo Nordisk AS $75.00 10/02/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723475
Principal investigator 1 PFIZER INC. $8,769.61 10/02/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 671663801
Recipient SANOFI PASTEUR INC. $593.45 09/28/2019 Covered Recipient Physician Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use No dispute reported 06/30/2026 691624857
Principal investigator 1 PFIZER INC. $5,429.39 09/19/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685771
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $126.37 09/19/2019 Non-covered Recipient Entity
M3 Wake Research, Inc
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685020493
Principal investigator 1 PFIZER INC. $2,242.72 08/27/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671686187
Principal investigator 1 PFIZER INC. $235.06 08/15/2019 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671663797
Principal investigator 1 PFIZER INC. $3,435.76 08/03/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685773
Principal investigator 1 Sunovion Pharmaceuticals Inc. $655.08 07/25/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914387
Principal investigator 1 Sunovion Pharmaceuticals Inc. $1,211.28 07/25/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914389
Principal investigator 1 Sunovion Pharmaceuticals Inc. $8.39 07/25/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632154875
Principal investigator 1 Sunovion Pharmaceuticals Inc. $15.52 07/25/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632154879
Principal investigator 1 PFIZER INC. $521.17 07/17/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671685705
Principal investigator 1 PFIZER INC. $13,844.32 07/12/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685703
Principal investigator 1 Novo Nordisk AS $23.93 07/10/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723477
Principal investigator 1 PFIZER INC. $3,281.39 07/09/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671686251
Principal investigator 1 PFIZER INC. $8,523.92 06/22/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685443
Principal investigator 1 PFIZER INC. $4,640.87 06/21/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671685441
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,250.00 06/21/2019 Non-covered Recipient Entity
M3 Wake Research, Inc
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685018889
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 06/21/2019 Non-covered Recipient Entity
M3 Wake Research, Inc
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685018891
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 06/21/2019 Non-covered Recipient Entity
M3 Wake Research, Inc
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685018895
Principal investigator 1 PFIZER INC. $97.50 06/19/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671644875
Principal investigator 1 Merck Sharp & Dohme Corporation $3,047.20 06/14/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 No dispute reported 06/30/2026 691333091
Principal investigator 1 Merck Sharp & Dohme Corporation $97.05 06/11/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 No dispute reported 06/30/2026 691346945
Principal investigator 1 Novo Nordisk AS $45.52 06/05/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723479
Principal investigator 1 Novo Nordisk AS $20.40 06/05/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723481
Principal investigator 1 Novo Nordisk AS $167.51 06/05/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723483
Principal investigator 1 PFIZER INC. $24,554.20 06/04/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685439
Principal investigator 1 PFIZER INC. $11,465.74 05/31/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671686191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $950.00 05/29/2019 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639739555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,000.00 05/29/2019 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639739557
Principal investigator 1 PFIZER INC. $200.38 05/28/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685635
Principal investigator 1 PFIZER INC. $8,338.72 05/23/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671685511
Principal investigator 1 PFIZER INC. $13,571.38 05/23/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671686189
Principal investigator 1 PFIZER INC. $1,148.56 05/22/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671624219
Principal investigator 1 PFIZER INC. $300.57 05/14/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685573
Principal investigator 1 PFIZER INC. $35,469.16 05/07/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685513
Principal investigator 1 PFIZER INC. $300.57 05/06/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685637
Principal investigator 1 PFIZER INC. $16,943.94 05/03/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671686119
Principal investigator 1 Novo Nordisk AS $20.01 04/25/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723485
Principal investigator 1 Novo Nordisk AS $20.01 04/25/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723487
Principal investigator 1 PFIZER INC. $1,148.56 04/24/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671626317
Principal investigator 1 PFIZER INC. $8,842.60 04/23/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671686117
Principal investigator 1 PFIZER INC. $271,882.78 04/19/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671686115
Principal investigator 1 Merck Sharp & Dohme Corporation $186.00 04/17/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. No dispute reported 06/30/2026 691489853
Principal investigator 1 PFIZER INC. $801.52 04/15/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685633
Principal investigator 1 Novo Nordisk AS $33.35 04/11/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723489
Principal investigator 1 Novo Nordisk AS $33.35 04/11/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723491
Principal investigator 1 Sunovion Pharmaceuticals Inc. $78,814.44 04/10/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914391
Principal investigator 1 Sunovion Pharmaceuticals Inc. $1,010.23 04/10/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632154883
Principal investigator 1 PFIZER INC. $26,527.80 04/09/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671686193
Principal investigator 1 PFIZER INC. $5,700.00 04/09/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671686253
Principal investigator 1 PFIZER INC. $701.33 04/02/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685701
Principal investigator 1 Merck Sharp & Dohme Corporation $8,838.00 03/21/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. No dispute reported 06/30/2026 691316375
Principal investigator 1 Merck Sharp & Dohme Corporation $1,161.00 03/04/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 No dispute reported 06/30/2026 691327173
Principal investigator 1 Flexion Therapeutics, Inc. $9,000.00 03/01/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis No dispute reported 06/30/2026 705979639
Principal investigator 1 PFIZER INC. $7,634.00 02/26/2019 Non-covered Recipient Entity
CAROLINA PHASE RESEARCH LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671664727
Principal investigator 1 PFIZER INC. $279.04 02/20/2019 Non-covered Recipient Entity
Carolina Phase 1 Research LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671618437
Principal investigator 1 PFIZER INC. $70.00 02/19/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671644943
Principal investigator 1 PFIZER INC. $70.00 02/19/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671644945
Principal investigator 1 PFIZER INC. $6,512.00 02/19/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671686255
Principal investigator 1 Merck Sharp & Dohme Corporation $1,161.00 02/15/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 No dispute reported 06/30/2026 691327169
Principal investigator 1 Novo Nordisk AS $18.16 02/15/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723493
Principal investigator 1 Novo Nordisk AS $63.20 02/15/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723495
Principal investigator 1 Novo Nordisk AS $178.78 02/14/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723497
Recipient Bio Products Laboratory USA, Inc. $8,697.00 02/08/2019 Covered Recipient Physician RIG01 No dispute reported 06/30/2026 705328153
Principal investigator 1 PFIZER INC. $200.38 02/05/2019 Non-covered Recipient Entity
M3 Wake Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671686257
Principal investigator 1 PFIZER INC. $97.50 02/04/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES LLC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671618193
Principal investigator 1 Novo Nordisk AS $18.00 01/18/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
NN9536-4376 No dispute reported 06/30/2026 706723499
Principal investigator 1 Merck Sharp & Dohme Corporation $148.80 01/08/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 No dispute reported 06/30/2026 691489105
Principal investigator 1 Merck Sharp & Dohme Corporation $2,600.00 01/03/2019 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES, LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. No dispute reported 06/30/2026 691308285